PerkinElmer, Inc. Acquires Thermal Analysis Product Line From Triton Technology
* The DMA 8000 Provides a Powerful Solution for both Routine Analysis and Advanced Research * Serves as the Cornerstone for the Next Generation of PerkinElmer Thermal Technologies
PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today announced the acquisition of a line of Dynamic Mechanical Analysis (DMA) products from UK-based Triton Technology Ltd. The DMA instrument is used by scientists in the polymers, pharmaceuticals and food industries for diverse applications ranging from simple quality control to advanced research.
“This acquisition brings our customers a best-in-class thermal analysis tool that combines ease-of-use and flexibility with powerful performance,” said Robert F. Friel, president of PerkinElmer Life and Analytical Sciences. “The new DMA 8000 represents the type of novel, next-generation technology we are investing in to continually provide solutions to customers that enable them to advance the pace and precision of their research and testing.”
“We believe that this transaction will allow our DMA technology to flourish in the very capable hands of PerkinElmer, while releasing resources within Triton Technology Ltd. allowing us to bring forward the development of radical new technology for the QA/QC of polymeric materials,” said Glynn Van-de-Velde, director, Triton Technology Ltd. “Triton Technology will work very closely with PerkinElmer to ensure a smooth transition of the technology to the benefit of both existing and new customers alike.”
For more information, visit www.perkinelmer.com/dma8000.
Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.5 billion in 2005, has 8,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE. Contacts
PerkinElmer, Inc. Investor Relations: Steven Delahunt, 781-431-4258 or Media Contact: Kevin Lorenc, 781-431-4231